Markets
markets
Luke Kawa
8/29/25

Nvidia tumbles as China pushes toward an AI boom without the US juggernaut

What does an AI boom look like without Nvidia at its epicenter?

More and more, it seems that China is willing to test out those uncharted waters.

Shares of the $4 trillion chip designer are down more than 3% in early trading after The Wall Street Journal reported that Alibaba is developing a chip for AI inference tasks manufactured domestically, the latest in a series of signs that the country is looking to wean itself off of any dependence on Nvidia and US technology to develop its AI capabilities.

The Chinese AI market is of no small import to Nvidia. On the conference call following earnings this week, CEO Jensen Huang called it a $50 billion opportunity that he expects to grow at 50% per year.

But China has reportedly told its leading tech companies to forgo purchases of Nvidia’s H20 chips, citing data security concerns. These allegations regarding data security have been denied by Nvidia, and appear to reflect China’s desire to avoid having its AI development be beholden to the whims of US policymakers.

Nvidia had been effectively locked out of China’s AI market since mid-April, when export curbs were enacted, and didn’t receive licenses to ship H20 processors to the world’s second-largest economy until August. The chip designer reportedly halted production of these chips recently, which suggests that China’s directive to its tech giants has some teeth.

Without access to the most advanced technology, China will have to effectively make up for what it lacks in ability with volume.

This news also comes as other, smaller Chinese chipmakers begin to capture more attention from domestic investors. Cambricon, for instance, soared 15% to a record high earlier this week after reporting surging sales growth. Its share price more than doubled in a span of less than three weeks. Per the Financial Times, Chinese officials have told their biggest domestic chipmaker, SMIC, to devote some more capacity to Cambricon rather than give all the availability to Huawei Technologies, which is currently the country’s most advanced AI chip developer.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.